Introduction

Artificial intelligence is increasingly being used to explore the boundaries of synthetic biology, and a new conversation hosted by MIT Technology Review puts a spotlight on what happens when algorithms turn their attention to viral design. The discussion features Stanford PhD candidate Samuel King, who in 2025 used a generative AI model to outline genetic sequences for microscopic viruses.

What Happened

In 2025, Samuel King leveraged a generative AI model to propose preliminary genetic blueprints for microscopic viruses, marking one of the first publicized attempts to use machine learning for viral sequence design. The work was recognized through MIT Technology Review's Innovators Under 35 program, which highlights emerging leaders transforming technology. Senior AI reporter James O'Donnell sat down with King for a subscriber-only conversation, discussing the methods behind the AI-generated designs, the current limitations of the technology, and what the future might hold for AI-mediated life design. The event went live on October 16, 2026, with times scheduled for BST, EDT, and PDT audiences.

Why This Matters

The ability of AI to propose viral genetic sequences raises important questions about biosafety, ethical oversight, and the future trajectory of synthetic biology. While the technology is not yet capable of producing fully functional, self-replicating life, the pace of development suggests significant shifts in how researchers approach disease modeling, vaccine design, and biological risk assessment. Experts caution that without rigorous safeguards, the line between computational simulation and actual creation could blur rapidly, making ongoing dialogue between technologists, policymakers, and the scientific community essential.

Key Takeaways

  • Generative AI can produce plausible viral genetic sequences, but functional viability remains unproven.
  • The project was featured in MIT Technology Review's Innovators Under 35 initiative, spotlighting King as an emerging leader in bioengineering.
  • Direct dialogue between researchers and journalists helps contextualize hype and identify measurable progress in AI-driven biology.
  • Ongoing ethical frameworks and biosafety protocols are critical as AI tools become more capable in life sciences.
  • Subscribers gain access to live discussions, Q&A sessions, and deeper dives into the science behind the headlines.

Conclusion

As AI continues to intersect with biology, events like this conversation serve as a checkpoint for measuring progress, assessing risk, and guiding responsible innovation. Whether AI-designed viruses remain a research tool or evolve into a transformative force in medicine and beyond will depend on how the scientific community, regulators, and the public choose to steer the technology forward.